E-Mail
Los Angeles, Calif. - The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the addition of two monoclonal antibodies, BMS-986414 and BMS-986413, to the COVID-19 outpatient treatment study, ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. BMS-986414 and BMS-986413 will be administered as subcutaneous injections (shots) given at one visit. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple investigational agents for treating early COVID-19 in a single trial. For information about enrolling in the trial, please visit the study website. Given that prevention and treatment will continue to be an important part of ending the COVID-19 pandemic, it is key that we identify and develop a variety of treatment options, said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles (UCLA). ACTIV-2 is studying a number of different therapeutic approaches, including infusions, shots, pi